^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Squamous Cell Skin Cancer

    Related cancers:
    3d
    Integrative multi-omics identifies a diagnostic T cell signature for cutaneous squamous cell carcinoma. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Specifically, CYBA and S100A2 are identified as promising diagnostic candidate signatures, while APOE may reflect immunomodulatory heterogeneity. These findings offer insights for developing diagnostic strategies and targeted immunotherapies in cSCC.
    Journal • IO biomarker
    |
    FOXP3 (Forkhead Box P3) • APOE (Apolipoprotein E)
    6d
    Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=25, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Sep 2026 --> Feb 2027
    Trial primary completion date
    |
    Gilotrif (afatinib)
    6d
    A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=63, Completed, Incyte Corporation | Recruiting --> Completed
    Trial completion
    |
    INCB99280
    8d
    ETCABIO: Evaluation of Skin Tests in Biotherapy Allergies (clinicaltrials.gov)
    P=N/A, N=70, Not yet recruiting, University Hospital, Angers | Trial completion date: Oct 2027 --> Jun 2028 | Initiation date: Sep 2025 --> May 2026 | Trial primary completion date: Sep 2027 --> May 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    11d
    LANCE: FLASH Radiotherapy for Skin Cancer (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Centre Hospitalier Universitaire Vaudois | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> May 2026 | Trial primary completion date: Sep 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    11d
    Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (clinicaltrials.gov)
    P2, N=86, Recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2026 --> Mar 2026
    Trial initiation date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Erbitux (cetuximab) • Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
    11d
    NEOPECS: Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Melanoma and Skin Cancer Trials Limited | Trial completion date: Dec 2028 --> Dec 2030 | Trial primary completion date: Jan 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • Libtayo (cemiplimab-rwlc)
    11d
    The Role of the TG2-GPR56 Complex in Cutaneous Squamous Cell Carcinoma (CSCC) Aggression and Therapeutic Resistance. (PubMed, Int J Mol Sci)
    This molecular axis is particularly significant for its role in the maintenance of epidermal cancer stem (ECS) cells, which contribute to tumor progression and therapy resistance. While the definitive link between the TG2-GPR56 complex and systemic metastasis in cSCC is currently being elucidated, significant evidence from analogous malignancies and in vitro keratinocyte models provides a clear mechanistic roadmap for its involvement in tumor invasion.
    Review • Journal
    |
    TGM2 (Transglutaminase 2) • ADGRG1 (Adhesion G Protein-Coupled Receptor G1)
    11d
    THC and CBD Induce Heme Oxygenase-1-Dependent Cell Death and Trigger Mitochondrial Dysfunction in Human Melanoma and Cutaneous Squamous Cell Carcinoma Cells. (PubMed, Antioxidants (Basel))
    A more detailed functional analysis revealed an inhibition of mitochondrial oxygen consumption rate, accompanied by a decrease in various subunits of mitochondrial oxidative phosphorylation complexes. In conclusion, our data demonstrate a strong cytotoxic effect of THC and CBD on melanoma and cutaneous SCC cells involving mitochondrial apoptosis and mitochondrial dysfunction.
    Journal • PARP Biomarker
    |
    HMOX1 (Heme Oxygenase 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • CASP7 (Caspase 7) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha)
    11d
    C-POST: Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=415, Active, not recruiting, Regeneron Pharmaceuticals | Trial primary completion date: Nov 2026 --> Jan 2028
    Trial primary completion date
    |
    Libtayo (cemiplimab-rwlc)
    11d
    INTerpath-007: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (clinicaltrials.gov)
    P2/3, N=46, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)